Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2013
May 2013, Vol 4, No 4
May 2013, Vol 4, No 4
First Recipients of Bridge Grants to Support Hematologic Research Announced
Value Propositions
,
Value Peer-spectives
May 2013, Vol 4, No 4
Read Article
Powerful Algorithms Help Decipher the Genetics of Cancer
Value Propositions
,
Value Peer-spectives
May 2013, Vol 4, No 4
Using data-sifting algorithms developed by computer scientists at Brown University, researchers are beginning to untangle the complex genetics of cancer. In a new study published in the
New England Journal of Medicine,
investigators have outlined the most complete genetic profile of acute myeloid leukemia (AML).
Read Article
New Genomic Classification of Endometrial Cancers Will Soon Guide Therapy
Value Propositions
,
Value Peer-spectives
May 2013, Vol 4, No 4
Endometrial cancer is the fourth most common malignancy among American women. The National Cancer Institute estimates that close to 50,000 women will be diagnosed with endometrial cancer in 2013; for a majority of women with aggressive, high-grade tumors, the 5-year survival rate is approximately 16%.
Read Article
First Guidelines Issued for Molecular Diagnostics Use in Patients with Lung Cancer
Value Propositions
,
Value Peer-spectives
May 2013, Vol 4, No 4
After a decade of developing molecular diagnostics for lung cancer, 3 organizations have issued the first guidelines for testing for the EGFR mutation and ALK rearrangement in patients with lung cancer, the number one cancer-related killer worldwide, providing a valuable new tool to fully utilize the benefits of targeted therapies for this patient population.
Read Article
Many Patients Unwilling to Let Costs Influence the Treatment They Receive
In the Literature
May 2013, Vol 4, No 4
Involving patients in the cost discussion has been suggested as a way to begin to curb the rising costs of care. A new study investigated the inclination of Americans with health insurance to discuss their willingness to have cost as part of the decision-making in their care (Sommers R, et al.
Health Aff [Millwood]
. 2013;32:338-346).
Read Article
Only 57% of Specialty Societies Consider Costs in Clinical Recommendations
In the Literature
May 2013, Vol 4, No 4
Concerns for the cost implications of clinical decision-making by providers and health plans have increased significantly in the recent past, as well as the advice to consider cost in addition to efficacy as a part of the treatment paradigm.
Read Article
Charting the Landscape of Driver Mutations in Acute Myeloid Leukemia
In the Literature
May 2013, Vol 4, No 4
The role of acute myeloid leukemia (AML) mutations in the pathogenesis of the disease has not been fully understood, and many genomic mutations in AML remain unknown. A team of researchers has recently analyzed large databases of genetic mutations and has selected 200 adult cases of de novo AML for their new study, using a variety of methods of genomic sequencing (The Cancer Genome Atlas Research Network.
N Engl J Med
. 2013 May 1. [Epub ahead of print]).
Read Article
The Changing Oncology Landscape: Evolution or Revolution?
By
Audrey Andrews
NCCN Annual Conference
May 2013, Vol 4, No 4
Hollywood, FL—Panelists at the 2013 National Comprehensive Cancer Network (NCCN) annual conference view the oncology world as rapidly changing, and the impact of this, for better or for worse, will be felt by healthcare providers, payers, and patients alike.
Read Article
Ibrutinib Shows Rapid, Dramatic Responses in Patients with CLL
By
Charles Bankhead
AACR Annual Meeting
May 2013, Vol 4, No 4
Washington, DC—More than 50% of patients with difficult-to-treat chronic lymphocytic leukemia (CLL) had tumor shrinkage during 6 months of treatment with ibrutinib, results of a phase 2 clinical trial showed.
Read Article
For Florida Congresswoman with a History of Cancer, Genetic Patent Case Is Personal
By
Caroline Helwick
May 2013, Vol 4, No 4
Hollywood, FL—For the first time, the Annual Conference of the Association for Value-Based Cancer Care (AVBCC) was addressed by a member of Congress.
Read Article
Page 4 of 5
1
2
3
4
5
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma